Drug-Drug Interaction Between THC and AEF0117
- Conditions
- Cannabis Abuse
- Interventions
- Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-oneDrug: Placebo
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 24
- Registration Number
- NCT06395688
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 40
- Registration Number
- NCT05748405
- Locations
- 🇪🇸
Unidad de Adultos con SÃndrome de Down, Hospital de La Princesa, Madrid, Spain
🇪🇸Hospital del Mar Medical Research Institute (IMIM),, Barcelona, Catalonia, Spain
🇪🇸Sant Pau Memory Clinic, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 8
- Registration Number
- NCT05554926
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States
The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
- Conditions
- Marijuana Abuse
- Interventions
- Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting conditionDrug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 24
- Registration Number
- NCT05451017
- Locations
- 🇺🇸
Substance Use Research Center, New York, New York, United States
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 333
- Registration Number
- NCT05322941
- Locations
- 🇺🇸
Segal Trial, Lauderhill, Florida, United States
🇺🇸Cedar Clinical Research, Draper, Utah, United States
🇺🇸Cedar clinical research, Phoenix, Arizona, United States
AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.
- Conditions
- Safety, Tolerability, Pharmacokinetics of AEF0217
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 68
- Registration Number
- NCT05170737
- Locations
- 🇪🇸
Hospital del Mar Medical Research Institute (IMIM) Neurosciences Research Program, Barcelona, Spain
Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 29
- Registration Number
- NCT03717272
- Locations
- 🇺🇸
Substance Use Research Center, New York, New York, United States
Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AEF0117 oral capsuleDrug: Placebo oral capsule
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 24
- Registration Number
- NCT03443895
- Locations
- 🇺🇸
Biotrial Inc, Newark, New Jersey, United States
Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 40
- Registration Number
- NCT03325595
- Locations
- 🇺🇸
Biotrial Inc, Newark, New Jersey, United States